PNPLA3 and hepatocellular carcinoma: After stratification of patients according to the HCC stage at presentation (0-A-B vs. C–D), homozygosity for PNPLA3 148M was associated with lower survival in patients with less advanced (p = 0.015 at Log-Rank test; median survival 36, 95% c.i. 30–48 vs. 54, 95% c.i. 48–72 months; Figure 4A), but not in those with advanced disease (p = 0.57 at Log-Rank test; median survival 36, 95% c.i. 24–48 vs. 42, 95% c.i. 30–48 months; Figure 4B).